AI Longevity Daily

Today’s Summary

Parkinson's early human trial: a single cell injection gave patients roughly five extra hours of controlled symptoms per day.
Epigenetic reprogramming's first-in-human trial: three glaucoma patients tolerated it well, with two showing visual field improvement signals.
Both trials had no control groups and extremely small samples — these observational signals cannot be treated as efficacy confirmation.

🔥 Today’s Top 10 🔥

1. Parkinson’s Cell Therapy: One Shot Adds Five Hours of “Good Time” Daily

XellSmart’s XS411 is a dopamine neuron derived from induced pluripotent stem cells (ordinary cells reset to a pluripotent state and then redirected), surgically injected deep into the brain’s motor regions. In a Phase 1 trial of 9 Parkinson’s patients with an average disease duration of about ten years, a single transplant at the six-month mark gave patients an average of more than five extra hours per day of symptom-controlled time free of abnormal involuntary movements, with motor scores improving by more than 30 points on average — every participant exceeded the recognized clinically meaningful change threshold. ¹⁸F-DOPA PET scans showed increased dopamine synthesis activity at the injection site, supporting the judgment that cells survived. The therapy’s edge is that it skips donor-recipient immune matching in favor of a standardized immunosuppression protocol, which — if it holds up — dramatically lowers the barrier to scaled production. A 30-person Phase 2 trial has completed enrollment, using blinded outcome assessment; the control group data will be the real test. The 9-person sample can’t tell us anything about dose-response, and the company’s self-disclosed data still awaits independent verification. Check out Longevity.Technology’s coverage for trial design and imaging result details.

2. Epigenetic Reprogramming’s First Human Trial: Glaucoma Patients Show Visual Field Improvement Signals

Life Biosciences has released early Phase 1 human data for its glaucoma drug ER-100. ER-100 delivers three transcription factors (OCT4, SOX2, KLF4 — collectively OSK) into retinal ganglion cells via a single intravitreal injection, then activates expression with 56 days of oral doxycycline, aiming to “reset” damaged cells to a younger gene expression state — i.e., epigenetic repair. All 3 open-angle glaucoma patients tolerated it well, with no dose-limiting toxicity or serious adverse events; 2 of the 3 showed visual field improvement signals at day 56, with more than 28% of tested points in each patient improving by more than 4 decibels. The Data Safety Monitoring Board has recommended advancing to the second dose cohort. Phase 1 is designed only to assess safety and tolerability — 3 patients with no control group means the visual field improvements are preliminary observational signals, not efficacy confirmation. The full trial protocol is available at clinicaltrials.gov (NCT07290244) , and Lifespan.io’s coverage has a detailed data breakdown.

3. Can a One-Time Gut Procedure Lock In Weight-Loss Gains After Stopping GLP-1s?

Fractyl Health’s Revita is an endoscopic ablation procedure targeting the duodenum (the very first section of the small intestine), designed to reset the gut lining’s nutrient-sensing function. In the pivotal REMAIN-1 trial of 308 obese adults — all of whom had stopped tirzepatide and begun regaining weight — the Revita group rebounded by an average of 5.1% body weight at six months, versus 8.2% in the sham surgery group (p=0.0023). The Revita group preserved about 80% of their drug-induced weight loss, compared to 67% in the sham group. That said, the ~3 percentage point absolute difference isn’t huge, and the 53% reduction in regain figure comes from a post-hoc analysis of larger ablation areas — an exploratory finding. The real make-or-break moment is the 12-month data: the FDA requires that more than half of Revita patients still weigh at least 5% less than pre-drug baseline, with results expected in Q1 2027. Revita remains an investigational device in the US. See Longevity.Technology’s coverage for trial design and subgroup breakdowns.

4. NAD+ Pathway Activator Pairs With a Weight-Loss Shot — Phase 2 Trial Hits 50% Enrollment

Sironax is testing SIR4156, an oral small-molecule drug that activates the NAMPT enzyme. NAMPT is the key enzyme in the cell’s own NAD+ synthesis pathway — NAD+ being the molecule that regulates energy metabolism and muscle function, and that declines with age. Unlike NAD+ precursor supplements (like NMN), SIR4156 directly activates the synthesis pathway itself, making it a first-in-class approach. Paired with semaglutide (a GLP-1 weight-loss drug), the goal is to reduce muscle loss and improve body composition during weight loss. The global Phase 2 FORGE-LM trial has completed about 50% enrollment, in a randomized double-blind placebo-controlled design. The supporting evidence so far comes from mouse studies — no human results have been published yet — and muscle mass is a secondary endpoint, not the primary one. FDA approval is pending. Head to Longevity.Technology’s coverage for trial design details and NAD+ pathway background.

5. AI Drug Dev Company Insilico’s Mesothelioma Drug Shows Response Signals in Phase 1

Insilico Medicine presented first-in-human Phase 1 data for ISM6331 at the 2026 European Society for Medical Oncology congress. Among 36 enrolled patients (median 2 prior lines of therapy), 2 of 5 evaluable patients in the 130 mg once-daily cohort achieved objective responses (tumor shrinkage of 58% and 36%), giving that cohort an objective response rate of 40%. Across the full dose range (30–130 mg), 22 evaluable patients showed an overall response rate of 18.2% and a disease control rate of 68.2%. Three of the 4 responding patients showed response at the first scan at week 8. No dose-limiting toxicities were observed in the 15–130 mg range, with a Grade 3 adverse event rate of 8.3%. Mesothelioma is an aging-related refractory cancer, and this drug was designed with AI-assisted target and molecule identification. This is a small Phase 1 safety exploration with no control arm; a Phase 2 dose-optimization study will follow. See [Longevity.